Home News BioStock Investor Pitch: ExpreS2ion Biotechnologies

BioStock Investor Pitch: ExpreS2ion Biotechnologies


BioStock Investor Pitch: ExpreS2ion Biotechnologies

19 April, 2022

Biotech company ExpreS2ion Biotechnologies develops protein-based vaccines using its platform technology ExpreS2. Today, the pipeline consists of projects in four  indications: covid-19, breast cancer, influenza and malaria. The company is currently carrying out a rights issue of 73 million SEK to finance the completion of preclinical studies within the breast cancer project ES2B-C001, as well as to further develop the pipeline and strengthen its platform technology. CEO Bent U. Frandsen tells us more about ExpreS2ion’s vision in today’s BioStock Investor Pitch at 10:00.

See ExpreS2ion Biotechnologies CEO Bent U. Frandsen presents the company, in English, below.

YouTube video


The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev